Envestnet Portfolio Solutions Inc. Has $1.89 Million Position in Axon Enterprise, Inc (NASDAQ:AXON)

Envestnet Portfolio Solutions Inc. lowered its position in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 26.6% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,596 shares of the biotechnology company’s stock after selling 1,304 shares during the quarter. Envestnet Portfolio Solutions Inc.’s holdings in Axon Enterprise were worth $1,891,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of AXON. Pinion Investment Advisors LLC lifted its stake in Axon Enterprise by 3.0% in the first quarter. Pinion Investment Advisors LLC now owns 649 shares of the biotechnology company’s stock valued at $341,000 after buying an additional 19 shares in the last quarter. Beacon Pointe Advisors LLC lifted its stake in Axon Enterprise by 2.6% in the fourth quarter. Beacon Pointe Advisors LLC now owns 864 shares of the biotechnology company’s stock valued at $513,000 after buying an additional 22 shares in the last quarter. Fielder Capital Group LLC lifted its stake in Axon Enterprise by 2.2% in the fourth quarter. Fielder Capital Group LLC now owns 1,176 shares of the biotechnology company’s stock valued at $699,000 after buying an additional 25 shares in the last quarter. Interchange Capital Partners LLC lifted its stake in Axon Enterprise by 1.9% in the fourth quarter. Interchange Capital Partners LLC now owns 1,310 shares of the biotechnology company’s stock valued at $779,000 after buying an additional 25 shares in the last quarter. Finally, Quadrant Capital Group LLC lifted its stake in Axon Enterprise by 2.1% in the fourth quarter. Quadrant Capital Group LLC now owns 1,198 shares of the biotechnology company’s stock valued at $712,000 after buying an additional 25 shares in the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on AXON. The Goldman Sachs Group boosted their price objective on shares of Axon Enterprise from $730.00 to $830.00 and gave the stock a “buy” rating in a research report on Wednesday, May 14th. Needham & Company LLC boosted their price objective on shares of Axon Enterprise from $600.00 to $750.00 and gave the stock a “buy” rating in a research report on Thursday, May 8th. Barclays boosted their price objective on shares of Axon Enterprise from $726.00 to $735.00 and gave the stock an “overweight” rating in a research report on Friday, May 9th. Bank of America boosted their price objective on shares of Axon Enterprise from $750.00 to $895.00 and gave the stock a “buy” rating in a research report on Wednesday, June 4th. Finally, Craig Hallum lowered shares of Axon Enterprise from a “buy” rating to a “cautious” rating in a research report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $699.55.

Axon Enterprise Price Performance

Shares of AXON opened at $783.24 on Tuesday. The firm has a market capitalization of $60.98 billion, a PE ratio of 189.19, a PEG ratio of 89.48 and a beta of 1.29. The company’s 50-day moving average is $696.32 and its 200-day moving average is $625.93. Axon Enterprise, Inc has a fifty-two week low of $279.02 and a fifty-two week high of $806.64. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.83 and a quick ratio of 2.62.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.07. The company had revenue of $603.63 million for the quarter, compared to analyst estimates of $585.67 million. Axon Enterprise had a net margin of 14.86% and a return on equity of 5.81%. The company’s revenue was up 31.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.15 earnings per share. Equities analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Insider Buying and Selling

In other Axon Enterprise news, CAO Jennifer H. Mak sold 75 shares of the stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $771.81, for a total transaction of $57,885.75. Following the sale, the chief accounting officer now directly owns 15,240 shares in the company, valued at $11,762,384.40. This represents a 0.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, President Joshua Isner sold 905 shares of the stock in a transaction dated Tuesday, June 17th. The stock was sold at an average price of $776.39, for a total transaction of $702,632.95. Following the sale, the president now owns 268,735 shares in the company, valued at $208,643,166.65. The trade was a 0.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 44,642 shares of company stock valued at $30,500,428. 5.70% of the stock is owned by company insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.